SCHEMBL926908

SCHEMBL926908

COC(=O)N1CCCc2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.68
KDM4E B2RXH2 1/20 0.67
MAPT P10636 1/20 0.63
TSHR P16473 3/20 0.62
ALDH1A1 P00352 2/20 0.62
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 2/20 0.59
MAPK1 P28482 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
GAA P10253 1/20 0.59
SIGMAR1 Q99720 1/20 0.58
HTT P42858 1/20 0.58
PDE4A P27815 1/20 0.58
PDE4B Q07343 1/20 0.58
PDE4C Q08493 1/20 0.58
PDE4D Q08499 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039812 1.00 NOTUM (0.69) NOTUMSMN1; SMN2KDM4EMAPTTSHR
SCHEMBL30401717 0.98 NOTUM (0.67) NOTUMSMN1; SMN2KDM4EMAPTTSHR
SCHEMBL9530206 0.95 NOTUM (0.62) NOTUMSMN1; SMN2KDM4EMAPTTSHR
SCHEMBL30721522 0.90 NOTUM (0.67) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL5585204 0.90 NOTUM (0.67) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL5426108 0.84 NOTUM (0.65) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL3127747 0.83 NOTUM (0.63) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL5669846 0.83 NOTUM (0.63) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL22868259 0.83 MAPT (0.66) NOTUMSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL29476005 0.83 NOTUM (0.63) NOTUMSMN1; SMN2MAPTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 US disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 EP disclosed
CN-119403554-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 东丽株式会社 2025-02-07 CN disclosed
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2024-04-11 US disclosed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 EP disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 EP disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 EP disclosed
CN-116648245-A Tetrahydroquinoline derivative and medical application thereof 东丽株式会社 2023-08-25 CN disclosed
CN-113382991-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2022-12-27 CN disclosed
WO-2008047109-A1 THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-24 WO disclosed
EP-1881827-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2008-01-30 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 US disclosed
US-20070099960-A1 LXR receptor modulators LABORATOIRES FOURNIER S.A. (FR) 2007-05-03 US disclosed
EP-1719761-A1 NOVEL HETEROCYCLIC COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-11-08 EP disclosed
WO-2006114606-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2006-11-02 WO disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 EP disclosed
US-4401818-A HYPOTENSIVE AGENTS, CARDIOACTIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF AIFM2, TXNRD2, NFE2L2 NOTUM 4382/4885SMN1; SMN2 1074/4885KDM4E 2935/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 NOTUM 3096/4885SMN1; SMN2 10/4885KDM4E 2176/4885
US-20070099960-A1 LXR receptor modulators NR1H2, NR1H3, PPARD NOTUM 1043/4885SMN1; SMN2 2395/4885KDM4E 3026/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 NOTUM 4580/4885SMN1; SMN2 795/4885KDM4E 1759/4885
US-20070191447-A1 Novel heterocyclic compound OPRD1, GRIN3A, GRM3 NOTUM 3632/4885SMN1; SMN2 3709/4885KDM4E 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.